Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple spray shield cancer patients from radiation burns?

NCT ID NCT07704372

Symptom relief Sponsor: West China Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This trial tests whether a spray containing superoxide dismutase, an antioxidant enzyme, can reduce severe skin reactions caused by radiation therapy. Head and neck cancer patients scheduled for radiotherapy apply the spray five times daily to the treated skin area. The study compares the spray to a placebo to see if it lowers the chance of developing painful, peeling burns.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a topical superoxide dismutase skin spray
What this could lead to
If effective, this spray could offer a simple way to prevent painful skin burns during radiation therapy for head and neck cancer.
What could go wrong
This is a mid-stage trial with 140 participants, so results may not confirm benefit. The spray may not outperform placebo in reducing severe skin reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 140 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Histologically confirmed malignant tumors of the head and neck without distant metastasis. 2. Scheduled to undergo either postoperative adjuvant radiotherapy or definitive radiotherapy, with or without concurrent chemotherapy. 3. Age 18-80 years at the time of consent. 4. Eastern Cooperative Oncology Group (ECOG) performance status 0-2. 5. Signed informed consent form. 6. Adequate cognitive and reading abilities to complete the questionnaire. Exclusion Criteria: 1. Pre-existing skin disease or open wounds in the irradiation field. 2. Have a history of head and neck radiotherapy. 3. Autoimmune or connective tissue disorders affecting skin. 4. Known allergy to any component of study formulations. 5. Any condition that, in the investigator's judgment, would interfere with study participation or outcome assessment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Head and neck cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck cancer Head and Neck Neoplasms radiodermatitis prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Radiation-induced dermatitis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Sichuan University West China Hospital

    Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.